- Innovative deep learning algorithms allow a successful virtual screening of anti-osteoporosis natural compounds
- Aladdin´s proprietary deep learning model validated by the leading European Journal of Medicinal Chemistry
- Validation processes proved the superiority of Aladdin´s proprietary models compared to other baseline models and peers
BERLIN/LONDON November 09, 2020 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, successfully validated its deep learning algorithms (P-SAMPNN) - Pre-trained Self-Attentive Message Passing Neural Network - for drug discovery. The European Journal of Medicinal Chemistry, a global impactful journal about medical chemistry, accepted and published Aladdin´s and its partners´ research paper on the discovery of highly potent anti-osteoporosis natural products by means of deep learning algorithms. The research paper has been partly published at www.sciencedirect.com.
Working together with scientific renowned partners, such as the State Key Laboratory of Applied Microbiology Southern China and the School of Pharmaceutical Sciences, Sun Yat-sen University, Aladdin could put its innovative technology and long year expertise at service of drug discovery to run an Artificial Intelligence (AI) assisted virtual screening of a commercially available library about natural compounds to regulate osteoclastogenesis, which is the formation process of osteoclasts, the bone-resorbing cells. A too high activity of osteoclasts in the human body is actually one of the main causes of osteoporosis.
Aladdin´s pre-trained deep learning method (P-SAMPNN) confirmed 5 from 10 selected hits through virtual screening of the natural products contained in the library. Among the confirmed hits, 2 compounds (AP-123/40765213 and AE-562/43462182) were actually the nanomolar inhibitors against osteoclastogenesis with a new scaffold. This work has proved that by integrating deep learning approaches with wet biological and chemical processes, the Pre-trained Self-Attentive Message Passing Neural Network (P-SAMPNN) is capable of expediting the drug discovery process and identifying nanomolar activity leads.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: “The further validation of our innovative pre-trained deep learning model shows the high-end AI-technology capability of Aladdin. Validation processes proved that the P-SAMPNN model is significantly superior to other baseline models. By reaching this key milestone, we are continuing our path towards further breakthroughs in AI drug discovery.”
Already in July this year, Aladdin announced the development of a new deep learning method for drug discovery with a superior performance, which was validated by the International Joint Conference on Artificial Intelligence (IJCAI), a world-leading organization for scientific purpose with focus on Artificial Intelligence (AI).
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
Website Link: www.aladdinid.com
TICKER SYMBOL: NMI
For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
CROSS ALLIANCE communication GmbH
Phone +49 89 1250 90330